• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Paratek Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010 Product Image

Paratek Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

  • ID: 1463831
  • December 2010
  • 37 pages
  • Global Markets Direct

Paratek Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Paratek Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Paratek Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Paratek Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, READ MORE >



List of Tables
List of Figures
Paratek Pharmaceuticals, Inc. Snapshot
Paratek Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Paratek Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Paratek Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Paratek Pharmaceuticals, Inc. – Pipeline Products Glance
Paratek Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Paratek Pharmaceuticals, Inc. – Drug Profiles
Tetracyclines for Asthma
Product Description
Mechanism of Action
R&D Progress
Tetracyclines for MS
Product Description
Mechanism of Action
R&D Progress
Tetracyclines for Rheumatoid Arthritis
Product Description
Mechanism of Action
R&D Progress
MAR Program
Product Description
Mechanism of Action
R&D Progress
Tetracyclines for SMA
Product Description
Mechanism of Action
R&D Progress
Tetracyclines for Stroke
Product Description
Mechanism of Action
R&D Progress
Tetracyclins For Clostridium
Product Description
Mechanism of Action
R&D Progress
Paratek Pharmaceuticals, Inc. – Pipeline Analysis
Paratek Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Paratek Pharmaceuticals, Inc. Pipeline Products By Target
Paratek Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Paratek Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Paratek Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Oct 27, 2004: Paratek Pharmaceuticals Presents Multiple Sclerosis Data At Society For Neuroscience Annual Meeting
Oct 27, 2004: Serono And Paratek Pharmaceuticals In Partnership To Develop A Novel Oral Treatment For Multiple Sclerosis
Financial Deals Landscape
Paratek Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
Paratek Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
Paratek Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
Paratek Pharmaceuticals, Inc. Detailed Deal Summary
Serono Enters Into An Agreement With Paratek Pharmaceuticals
Merck Enters Into Agreement With Paratek Pharmaceuticals
Paratek Pharmaceuticals Enters Into Co-Development With Medicines for Malaria Venture
Licensing Agreements
Paratek Pharmaceuticals Enters Into Licensing Agreement With Novartis
Warner Chilcott Enters Into Licensing Agreement With Paratek Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS